Orexigen Therapeutics (OREX) Tops Q3 EPS by 7c, Revenue Misses
Tweet
Share
E-mailGet Alerts OREX Hot Sheet
Price: $0.22 --0%
Financial Fact:
Loss from operations: 42.53M
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
Loss from operations: 42.53M
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Orexigen Therapeutics (NASDAQ: OREX) reported Q3 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $10 million versus the consensus estimate of $12.17 million.
For earnings history and earnings-related data on Orexigen Therapeutics (OREX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- L3Harris CEO steps down amid conduct review, shares drop
- Nuvve Holdin (NVVE) Misses Q2 EPS by 1445c
- The LGL Group (LGL) Misses Q2 EPS by 8c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
